These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 24844045

  • 1. Bias at the gate?: The pharmaceutical industry's influence on the federally approved drug compendia.
    Gabrielsen L.
    Am J Law Med; 2014; 40(1):141-63. PubMed ID: 24844045
    [No Abstract] [Full Text] [Related]

  • 2. Off-label promotion: government theories of prosecution and facts that drive them.
    Burroughs AD, Levy MC, Schwab GG, Paik Y.
    Food Drug Law J; 2010; 65(3):555-88. PubMed ID: 24479242
    [No Abstract] [Full Text] [Related]

  • 3. Off-label drug use and promotion: balancing public health goals and commercial speech.
    Kesselheim AS.
    Am J Law Med; 2011; 37(2-3):225-57. PubMed ID: 21847880
    [No Abstract] [Full Text] [Related]

  • 4. Targeting drug companies' bottom line.
    Prescrire Int; 2011 Jan; 20(112):25. PubMed ID: 21462792
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. GlaxoSmithKline is fined record $3bn in US.
    Roehr B.
    BMJ; 2012 Jul 03; 345():e4568. PubMed ID: 22761252
    [No Abstract] [Full Text] [Related]

  • 7. Pharmaceuticals and medical devices: FDA oversight. Issue brief.
    Thomson Reuters/West.
    Issue Brief Health Policy Track Serv; 2011 Jan 03; ():1-39. PubMed ID: 21374841
    [No Abstract] [Full Text] [Related]

  • 8. Regulation of pharmacoeconomics and outcomes research.
    Radensky P.
    Value Health; 2001 Jan 03; 4(1):12-5. PubMed ID: 11704968
    [No Abstract] [Full Text] [Related]

  • 9. Evaluating promotional claims as false or misleading.
    Brushwood DB, Knox CA, Liu W, Jenkins KA.
    Am J Health Syst Pharm; 2013 Nov 01; 70(21):1941-4. PubMed ID: 24128969
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Manufacturers' promotion of off-label drug use: implications for drug safety.
    Zieve A, Carome MA.
    Expert Opin Drug Saf; 2016 Sep 01; 15(9):1149-51. PubMed ID: 27145440
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Quality of evidence in drug compendia supporting off-label use of typical and atypical antipsychotic medications.
    Paczynski RP, Alexander GC, Chinchilli VM, Kruszewski SP.
    Int J Risk Saf Med; 2012 Jan 01; 24(3):137-46. PubMed ID: 22936056
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. An unhealthy disregard.
    Nat Med; 2010 Jun 01; 16(6):609. PubMed ID: 20526289
    [No Abstract] [Full Text] [Related]

  • 17. After Amarin v FDA: What Will the Future Hold for Off-label Promotion Regulation?
    Mackey TK, Liang BA.
    Mayo Clin Proc; 2016 Jun 01; 91(6):701-6. PubMed ID: 27084416
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.